Q32 Bio posts positive bempikibart Phase 2a data, plans registration study for 2027

Q32 Bio Inc. reported financial results for the quarter ended June 30, 2026, and gave a corporate update on August 5, 2026. The company reported positive 36-week topline results from Part B of the SIGNAL-AA Phase 2a clinical trial, an open-label study evaluating bempikibart, a fully human anti-IL-7Rα antibody, in 33 patients with severe or very severe alopecia areata.¹

On the primary endpoint, bempikibart demonstrated a mean percent reduction in Severity of Alopecia Tool score from baseline of 35.3% in the prespecified modified intent-to-treat analysis.¹ In addition, 40.0% of patients achieved a SALT-20 response at Week 36 in the mITT analysis, and 30.3% achieved that response in the intent-to-treat analysis of all enrolled patients.¹ The company said bempikibart was generally well tolerated, consistent with prior studies, with no new safety signals.¹ Additional Week 36 data and initial findings from the off-drug period through Week 52 are expected to be presented at a medical meeting in the second half of 2026.¹

Patient enrollment and dosing in the SIGNAL-AA Part B open-label extension remain ongoing,¹ and Q32 Bio anticipates data from that extension in the second half of 2027.¹ The company plans to advance bempikibart in severe or very severe alopecia areata into a registration-directed program in the first half of 2027, subject to planned regulatory discussions in the second half of 2026.¹ Separately, Q32 Bio said its half-life extended anti-IL-7Rα antibody, ADX-914-XL, is advancing in pre-clinical development.¹

On financing, Q32 Bio completed a public offering of common stock and pre-funded warrants in July 2026, raising gross proceeds of approximately $200.0 million.¹ Cash and cash equivalents were $106.3 million as of June 30, 2026, which excludes proceeds from the July offering.¹ The company said this cash, combined with the July offering proceeds, is expected to be sufficient to fund operations through topline Phase 3 results from its planned registration-directed program in severe or very severe alopecia areata.¹